PROPHET is a prospective study in order to clarify a diagnostic impact of laboratory-based and prostate volume-adjusted [-2]proPSA-related indices on prostate cancer and a clinically significant prostate cancer in the PSA below 10 ng/mL.Between April 2015 and March 2017, 421 men aged 50 to 79 in the PSA range above age-specific cut-offs and below 10 ng/mL were registered in the PROPHET.
[Linking template=”default” type=”products” search=”what is a northern blot” header=”2″ limit=”156″ start=”2″ showCatalogNumber=”true” showSize=”true” showSupplier=”true” showPrice=”true” showDescription=”true” showAdditionalInformation=”true” showImage=”true” showSchemaMarkup=”true” imageWidth=”” imageHeight=””]
Diagnostic impacts of various clinical laboratory-based free PSA-related and [-2]proPSA-related indices on any grade and high Gleason grade group prostate cancer were investigated.Out of 363 eligible participants, 179, 141 and 80 were diagnosed with any grade prostate cancer, Gleason grade group 2-5 and 3-5 prostate cancer, respectively.